Clinical trials
Multiple Sclerosis trials in Denmark
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
83 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2003 | 1 |
| 2004 | 1 |
| 2006 | 7 |
| 2007 | 4 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2011 | 6 |
| 2012 | 4 |
| 2013 | 3 |
| 2014 | 4 |
| 2015 | 1 |
| 2016 | 4 |
| 2017 | 6 |
| 2018 | 10 |
| 2020 | 5 |
| 2021 | 4 |
| 2022 | 1 |
| 2023 | 4 |
| 2024 | 3 |
| 2025 | 4 |
| 2026 | 4 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 50 |
| Unknown status | 11 |
| Recruiting | 9 |
| Active, not recruiting | 7 |
| Terminated | 4 |
| Not yet recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| University of Aarhus | 15 |
| Biogen | 8 |
| Bayer | 6 |
| Novartis Pharmaceuticals | 6 |
| University of Southern Denmark | 6 |
| Rigshospitalet, Denmark | 4 |
| Sanofi | 4 |
| Genzyme, a Sanofi Company | 3 |
| Glostrup University Hospital, Copenhagen | 3 |
| Hoffmann-La Roche | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Multiple Sclerosis | 83 |
| Multiple Sclerosis, Relapsing-Remitting | 10 |
| Multiple Sclerosis, Chronic Progressive | 9 |
| Fatigue | 3 |
| Optic Neuritis | 3 |
| Recurrence | 3 |
| Autoimmune Diseases | 2 |
| Demyelinating Diseases | 2 |
| Amyotrophic Lateral Sclerosis | 1 |
| Arthritis, Psoriatic | 1 |
Trials
Showing 26 to 50 of 83. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.